查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715329

心臟生物标记诊断试剂套件市场：按生物标记类型、适应症、检测类型、购买类型、应用和最终用户划分－2025-2030 年全球预测

Cardiac Biomarker Diagnostic Kits Market by Biomarker Type, Indication, Testing Type, Purchasing Mode, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

心臟生物标记诊断套件市场预计在 2024 年价值 32.2 亿美元，2025 年价值 34.5 亿美元，预计到 2030 年将达到 49 亿美元，复合年增长率为 7.22%。

主要市场统计数据
基准年2024年 32.2亿美元
预计2025年 34.5亿美元
预测年份 2030 49亿美元
复合年增长率（%） 7.22%

心臟生物标记诊断套件市场处于医疗创新的前沿，满足了心血管评估和患者照护的关键需求。近年来，早期发现和早期疗育的需求推动了诊断准确性的提高。由于心血管疾病仍然是世界各地导致死亡的主要原因之一，将先进的诊断试剂套件整合到临床实践中已经变得至关重要。

报告首先概述了市场格局，并强调了从传统测试方法到尖端自动化平台的演变。分析表明，正在进行的研究、监管合作和技术突破不仅满足了当前的医疗保健需求，而且还为未来的诊断趋势设定了步伐。本书以资料主导的见解为基础，强调了利用这些先进诊断工具的临床和经济效益。

透过探索市场驱动因素、挑战和新兴机会，本介绍为深入讨论转型转变、关键细分、区域发展、主要参与者、实用建议以及采取果断行动的关键呼吁奠定了基础。这里彙编的见解旨在指南专家、临床决策者和行业相关人员应对这个动态发展的市场。

重新定义诊断格局的转折点

诊断领域经历了一场变革性的转变，重新定义了心臟疾病的检测和治疗方式。从历史上看，依赖传统的实验室检测方法限制了早期心血管干预所需的速度和准确性。然而，最近的技术进步正在推动诊断试剂套件向更快、更可靠和多功能的模式转移。

先进的诊断成像技术与数位健康解决方案的融合在这一演变中发挥关键作用。现代诊断设备现在可以实现即时资料收集，有助于加快关键测试结果。自动化和复杂的生物检测技术的整合正在简化业务，从而减少人为错误并提高诊断结果的可重复性。

此外，监管机构也认识到这些创新的变革力量，为突破性诊断工具提供快速核准，并创造竞争性的研发环境。即时检验的引入进一步体现了这种转变，确保可以直接在患者床边进行高品质的诊断，而不仅仅是在专科实验室进行。

在精准医疗快速崛起的时代，心臟生物标记诊断试剂套件的进步有助于制定个人化的治疗方案。随着临床实验室和医院越来越多地采用这些技术，整个医疗保健生态系统将受益于患者治疗效果的改善和诊断效率的提高。

影响市场动态的关键细分洞察

对市场细分的详细分析揭示了关键见解，突显了心臟生物标记诊断套件领域的多样性和复杂性。当考虑生物标记的类型时，市场会针对 B 型利钠肽、C 反应蛋白、心肌肌钙蛋白、肌酸激酶-MB 和肌红蛋白进行详细分析。这些生物标记在诊断和监测心血管功能方面都发挥着独特的作用，可提供广泛的应用来满足不同的临床需求。

除了生物标记分类外，诊断试剂套件还将根据适应症进行评估，重点领域是心绞痛、心臟衰竭和心肌梗塞。这种分类不仅与常见的心臟疾病相吻合，而且还为这些套件在不同患者情况下的临床部署提供了见解。此矩阵根据测试类型进一步细分，区分体外和体内测试环境。这种细分突显了诊断解决方案对不同临床环境和监管标准的适应性。

此外，采购模型透过将市场状况分为直接采购和第三方供应商，反映了产业内的业务偏好和供应链动态，这对了解市场趋势有很大帮助。应用评估着重于实验室检测和监测应用，前者进一步分为中央实验室检测和就地检验。这种复杂的细分凸显了与更即时的床边诊断需求相比，业务如何在集中环境中利用先进技术。

最后，基于最终用户的细分包括学术和研究机构、诊断实验室以及医院和诊所。对最终用户资料的详细剖析为目标市场提供了宝贵的见解，并有助于资源分配，以确保诊断套件符合不同操作环境的严格标准。总体而言，这种細項分析可作为将技术创新与实际市场需求相结合的蓝图，从而增强产品开发和策略市场开发。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球心血管疾病盛行率不断上升
      • 医疗保健专业人员越来越意识到准确的心臟诊断方法的重要性
      • 不健康生活型态及相关风险因素激增
    • 限制因素
      • 与样品采集和製备程序相关的复杂性
    • 机会
      • 利用巨量资料和预测分析来提高心臟诊断的准确性和效率
      • 生物标记检测方法的技术进步
    • 任务
      • 心臟生物标记诊断套件的复杂监管核准流程
  • 市场区隔分析
    • 生物标记类型：B型利钠肽在心臟衰竭诊断和监测中的重要性日益增强
    • 应用：扩大心臟生物标记诊断套件在实验室检测的应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 心臟生物标记诊断试剂套件市场（依生物标记类型）

  • B型利钠肽
  • C反应蛋白
  • 心臟肌钙蛋白
  • 肌酸激酶MB
  • 肌红蛋白

第七章心臟生物标记诊断试剂套件市场（按适应症）

  • 心绞痛
  • 心臟衰竭
  • 心肌梗塞

8. 心臟生物标记诊断试剂套件市场（依测试类型）

  • 体外测试
  • 体内测试

9. 心臟生物标记诊断试剂套件市场（按购买模式）

  • 直接购买
  • 第三方供应商

第 10 章：心臟生物标记诊断试剂套件市场（按应用）

  • 实验室测试
    • 中央实验室测试
    • 就地检验
  • 调查应用

第 11 章心臟生物标记诊断试剂套件市场（按最终用户）

  • 学术研究所
  • 诊断实验室
  • 医院和诊所

12.美洲心臟生物标记诊断试剂套件市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区心臟生物标记诊断试剂套件市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲心臟生物标记诊断套件市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Atlas Medical GmbH
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • Eurolyser Diagnostica GmbH
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Diagnostics, Inc.
  • GenWay Biotech, Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • J.Mitra & Co. Pvt. Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic Inc.
  • Meridian Bioscience, Inc.
  • MP Biomedicals, LLC
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthcare GmbH
  • Singulex, Inc.
  • SSI Diagnostica A/S Group
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Trivitron Healthcare
  • Tulip Diagnostics（P）Ltd
Product Code: MRR-433AB1DC288A

The Cardiac Biomarker Diagnostic Kits Market was valued at USD 3.22 billion in 2024 and is projected to grow to USD 3.45 billion in 2025, with a CAGR of 7.22%, reaching USD 4.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.22 billion
Estimated Year [2025] USD 3.45 billion
Forecast Year [2030] USD 4.90 billion
CAGR (%) 7.22%

The cardiac biomarker diagnostic kits market stands at the forefront of medical innovation, addressing critical needs in cardiovascular assessment and patient care. In recent years, the enhancement in diagnostic precision has been driven by the demand for early detection and intervention. As cardiovascular diseases continue to represent one of the leading causes of global mortality, the integration of advanced diagnostic kits into clinical practice has become indispensable.

This report initiates with an overview of the market environment, highlighting the evolution from traditional testing methods to state-of-the-art automated platforms. Analysis reveals that ongoing research, regulatory collaborations, and technological breakthroughs are not only meeting current healthcare demands but are also setting the pace for future diagnostic trends. The narrative is supported by data-driven insights that underscore the clinical and economic benefits of leveraging these advanced diagnostic tools.

Through an exploration of market drivers, challenges, and emergent opportunities, this introduction lays the foundation for a detailed discourse on the transformative shifts, key segmentation, regional developments, prominent players, practical recommendations, and a conclusive call for decisive action. The insights compiled herein are intended to guide professionals, clinical decision-makers, and industry stakeholders in navigating this dynamically evolving market.

Transformative Shifts Redefining the Diagnostic Landscape

The diagnostic landscape has witnessed transformative shifts that have redefined the manner in which cardiac conditions are detected and managed. Historically, the reliance on conventional laboratory testing methods limited the speed and accuracy required for early cardiovascular intervention. However, recent innovations have spurred a paradigm shift toward more rapid, reliable, and multifunctional diagnostic kits.

Advanced imaging techniques and the integration of digital health solutions have played a pivotal role in this evolution. Modern diagnostic instruments now facilitate real-time data collection that supports faster turnaround times for critical test results. The integration of automation and sophisticated bioassay technologies has streamlined operations, thereby reducing human error and enhancing the reproducibility of diagnostic outcomes.

Moreover, regulatory bodies have recognized the transformative power of these innovations, offering expedited pathways for the approval of breakthrough diagnostic tools and fostering an environment of competitive research and development. The introduction of point-of-care testing further exemplifies this shift, ensuring that high-quality diagnostics are available not only in specialized laboratories but also directly at the patient's bedside.

In an era where precision medicine is rapidly emerging, the advancements in cardiac biomarker diagnostic kits have become instrumental in tailoring individualized treatment plans. As clinical laboratories and hospitals increasingly adopt these technologies, the entire healthcare ecosystem is benefiting from improved patient outcomes and enhanced diagnostic efficiency.

Key Segmentation Insights Shaping Market Dynamics

An in-depth analysis of the market segmentation reveals significant insights that underscore the diversity and complexity of the cardiac biomarker diagnostic kits sector. When considering biomarker type, the market is meticulously analyzed across B-Type Natriuretic Peptide, C-Reactive Protein, Cardiac Troponin, Creatine Kinase-MB, and Myoglobin. Each of these biomarkers plays a distinct role in diagnosing and monitoring cardiovascular functions, thereby offering a broad spectrum of applications that address varied clinical needs.

In addition to biomarker classification, the diagnostic kits are evaluated based on the indication, with key focus areas spanning Angina Pectoris, Heart Failure, and Myocardial Infarction. This categorization not only aligns with prevalent cardiac conditions but also offers insights into the clinical deployment of these kits in different patient scenarios. The matrix is further segmented by testing type, differentiating between In Vitro Testing and In Vivo Testing environments. Such segmentation highlights the adaptability of diagnostic solutions to different clinical settings and regulatory standards.

Furthermore, purchasing mode contributes significantly to understanding market behavior, as it categorizes the landscape into Direct Purchasing and Third-Party Suppliers, thereby reflecting the operational preferences and supply chain dynamics within the industry. When evaluating applications, the primary emphasis is on Laboratory Testing and Research Applications; the former is further dissected into Central Laboratory Testing and Point-of-Care Testing. This intricate breakdown underscores how operational implementers leverage advanced technology in centralized settings compared to more immediate, bedside diagnostic needs.

Finally, the segmentation based on end users encompasses Academic & Research Institutions, Diagnostic Laboratories, and Hospitals & Clinics. This detailed dissection of the end user profile provides valuable insights into target markets and helps in the allocation of resources to ensure that the diagnostic kits meet the rigorous standards of diverse operational environments. Overall, this segmentation analysis serves as a roadmap for aligning technological innovations with practical market requisites, thereby enhancing both product development and strategic market positioning.

Based on Biomarker Type, market is studied across B-Type Natriuretic Peptide, C-Reactive Protein, Cardiac Troponin, Creatine Kinase-MB, and Myoglobin.

Based on Indication, market is studied across Angina Pectoris, Heart Failure, and Myocardial Infarction.

Based on Testing Type, market is studied across In Vitro Testing and In Vivo Testing.

Based on Purchasing Mode, market is studied across Direct Purchasing and Third-Party Suppliers.

Based on Application, market is studied across Laboratory Testing and Research Applications. The Laboratory Testing is further studied across Central Laboratory Testing and Point-of-Care Testing.

Based on End User, market is studied across Academic & Research Institutions, Diagnostic Laboratories, and Hospitals & Clinics.

Key Regional Insights Influencing Market Growth

On a geographic scale, the cardiac biomarker diagnostic kits market exhibits nuanced trends across distinct regions, each contributing uniquely to overall market growth. In the Americas, a robust healthcare infrastructure combined with increasing investments in advanced medical diagnostics is catalyzing widespread adoption. The region's emphasis on preventive healthcare and chronic disease management has significantly boosted the demand for rapid and reliable diagnostic solutions.

In the Europe, Middle East & Africa region, a blend of stringent regulatory frameworks and a growing emphasis on personalized medicine is creating a conducive environment for the deployment of innovative diagnostic kits. The collaborative initiatives between public health institutions and private players are leading to enhanced technology transfer and market penetration.

Meanwhile, the Asia-Pacific region is emerging as a critical hub, driven by economic growth, rising awareness about cardiovascular health, and significant government support for healthcare innovation. The dynamic nature of this market showcases an increasing appetite for advanced diagnostics in both urban centers and remote locations, thereby fostering a more inclusive and comprehensive healthcare approach.

Taken together, these regional insights illustrate how local market conditions, regulatory landscapes, and socio-economic factors collaboratively shape the global outlook of the cardiac biomarker diagnostic kits sector.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Shaping Industry Leadership

The industry is characterized by the strategic maneuvers and pioneering efforts of several leading companies, who continue to drive innovation and competitive differentiation within the cardiac biomarker diagnostic kits market. Global giants such as Abbott Laboratories, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. remain at the forefront by consistently enhancing their product portfolios. They have set high benchmarks in terms of accuracy, speed, and clinical relevance, ensuring their methodologies resonate with the evolving requirements of healthcare providers.

In parallel, companies like Atlas Medical GmbH, bioMerieux SA, and Creative Diagnostics are leveraging niche expertise to address specialized diagnostic challenges. Other prominent players, including Eurolyser Diagnostica GmbH and F. Hoffmann-La Roche Ltd., have integrated advanced automation and data analytics into their workflows, reshaping the landscape for rapid diagnostics.

Fujirebio Diagnostics, Inc., GenWay Biotech, Inc., and Guangzhou Wondfo Biotech Co., Ltd. have further contributed to the market by introducing innovative platforms that merge clinical-grade performance with cost-efficiency. J.Mitra & Co. Pvt. Ltd. and Lepu Medical Technology (Beijing) Co., Ltd. are renowned for their commitment to developing robust diagnostic tools adaptable across varied healthcare settings.

Additionally, Medtronic Inc. and Meridian Bioscience, Inc. have expanded their global presence by tapping into regulatory advancements and market-specific trends. MP Biomedicals, LLC, Radiometer Medical ApS, and Randox Laboratories Ltd. continue to invest significantly in research and development, ensuring their offerings are both cutting-edge and clinically relevant. Siemens Healthcare GmbH, Singulex, Inc., SSI Diagnostica A/S Group, Thermo Fisher Scientific, Inc., Tosoh Corporation, Trivitron Healthcare, and Tulip Diagnostics (P) Ltd. further enrich the competitive fabric of the market through strategic partnerships and continuous innovation.

Collectively, these companies form a competitive mosaic where excellence is driven by customization, technological integration, and a firm commitment to quality, all aimed at elevating standards of patient care across a broad spectrum of clinical settings.

The report delves into recent significant developments in the Cardiac Biomarker Diagnostic Kits Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Atlas Medical GmbH, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., bioMerieux SA, Creative Diagnostics, Eurolyser Diagnostica GmbH, F. Hoffmann-La Roche Ltd., Fujirebio Diagnostics, Inc., GenWay Biotech, Inc., Guangzhou Wondfo Biotech Co., Ltd., J.Mitra & Co. Pvt. Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Medtronic Inc., Meridian Bioscience, Inc., MP Biomedicals, LLC, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthcare GmbH, Singulex, Inc., SSI Diagnostica A/S Group, Thermo Fisher Scientific, Inc., Tosoh Corporation, Trivitron Healthcare, and Tulip Diagnostics (P) Ltd. Actionable Recommendations for Forward-Thinking Industry Leaders

Industry leaders seeking to excel in the cardiac biomarker diagnostic kits segment must align strategic investments with future market trends. It is essential to harness the power of data analytics and artificial intelligence, integrating real-time diagnostic data with predictive modeling to enhance decision-making and patient outcomes. Emphasizing research collaborations with academic and clinical institutions can drive the development of next-generation biomarker assays, ultimately expanding the scope and accuracy of diagnostic solutions.

Leaders should also focus on adopting an agile supply chain model, one that leverages both direct purchasing and strategic alliances with third-party suppliers, ensuring that the latest diagnostic innovations are seamlessly integrated into healthcare systems. Exploring diversified testing modalities by streamlining the offerings between central laboratory testing and point-of-care environments will not only broaden market penetration but also cater to the diverse needs of clinical settings.

Investing in training and ongoing education for healthcare professionals is critical for maximizing the potential of advanced diagnostic tools. This, in turn, reinforces the quality of patient care while simultaneously driving market adoption. Embracing regulatory compliance and ensuring alignment with emerging global standards is equally vital, as it bolsters trust and facilitates smoother market entry.

By maintaining a proactive stance in technology adoption, research partnerships, and process optimization, industry leaders can build resilient business models that not only respond to current market dynamics but also anticipate future shifts. This holistic approach ensures sustainable competitive advantages and positions organizations at the forefront of diagnostic innovation.

Conclusion: Charting a Course for a Diagnostic Revolution

As the cardiac biomarker diagnostic kits market continues to expand, the confluence of technological innovations, strategic market segmentation, and evolving regional dynamics paints a promising picture for the future. The detailed examination of biomarker types, clinical indications, testing modalities, purchasing preferences, and end-user dynamics reveals a complex yet highly adaptable market ecosystem.

The competitive landscape, bolstered by both established industry giants and innovative newcomers, underscores a collective drive towards precision, reliability, and enhanced patient care. As this market evolves, the integration of advanced diagnostics into routine clinical practice will become even more critical, paving the way for faster clinical interventions and improved health outcomes.

In summation, the insights provided in this review serve as a vital tool for stakeholders aiming to navigate the intricacies of the evolving diagnostic landscape, fostering a culture of continuous improvement and strategic foresight.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cardiovascular diseases globally
      • 5.1.1.2. Growing awareness among healthcare professionals about the importance of accurate cardiac diagnosis methods
      • 5.1.1.3. Surge in unhealthy lifestyles and related risk factors
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with sample collection and preparation procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging big data for predictive analytics to enhance cardiac diagnostic precision and efficiency
      • 5.1.3.2. Technological advancements in biomarker detection methods
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory approval process for cardiac biomarker diagnostic kits
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Rising significance of B-type natriuretic peptide for diagnosing and monitoring heart failure
    • 5.2.2. Application: Expanding application of cardiac biomarker diagnostic kits in laboratory testing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Biomarker Diagnostic Kits Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. B-Type Natriuretic Peptide
  • 6.3. C-Reactive Protein
  • 6.4. Cardiac Troponin
  • 6.5. Creatine Kinase-MB
  • 6.6. Myoglobin

7. Cardiac Biomarker Diagnostic Kits Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Heart Failure
  • 7.4. Myocardial Infarction

8. Cardiac Biomarker Diagnostic Kits Market, by Testing Type

  • 8.1. Introduction
  • 8.2. In Vitro Testing
  • 8.3. In Vivo Testing

9. Cardiac Biomarker Diagnostic Kits Market, by Purchasing Mode

  • 9.1. Introduction
  • 9.2. Direct Purchasing
  • 9.3. Third-Party Suppliers

10. Cardiac Biomarker Diagnostic Kits Market, by Application

  • 10.1. Introduction
  • 10.2. Laboratory Testing
    • 10.2.1. Central Laboratory Testing
    • 10.2.2. Point-of-Care Testing
  • 10.3. Research Applications

11. Cardiac Biomarker Diagnostic Kits Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutions
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics

12. Americas Cardiac Biomarker Diagnostic Kits Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Cardiac Biomarker Diagnostic Kits Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Cardiac Biomarker Diagnostic Kits Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Siemens Atellica IM TnIH test gets FDA approval to predict cardiac events
    • 15.3.2. Cardio Diagnostics Holdings Inc. launched a redesigned website, CDIO.AI to enhance cardiovascular solutions
    • 15.3.3. Siemens Healthineers enhanced its Atellica cardiac testing menu with the NT-proBNPII assay
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Atlas Medical GmbH
  • 3. Beckman Coulter, Inc.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Creative Diagnostics
  • 7. Eurolyser Diagnostica GmbH
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Fujirebio Diagnostics, Inc.
  • 10. GenWay Biotech, Inc.
  • 11. Guangzhou Wondfo Biotech Co., Ltd.
  • 12. J.Mitra & Co. Pvt. Ltd.
  • 13. Lepu Medical Technology (Beijing) Co., Ltd.
  • 14. Medtronic Inc.
  • 15. Meridian Bioscience, Inc.
  • 16. MP Biomedicals, LLC
  • 17. Radiometer Medical ApS
  • 18. Randox Laboratories Ltd.
  • 19. Siemens Healthcare GmbH
  • 20. Singulex, Inc.
  • 21. SSI Diagnostica A/S Group
  • 22. Thermo Fisher Scientific, Inc.
  • 23. Tosoh Corporation
  • 24. Trivitron Healthcare
  • 25. Tulip Diagnostics (P) Ltd

LIST OF FIGURES

  • FIGURE 1. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET MULTI-CURRENCY
  • FIGURE 2. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET MULTI-LANGUAGE
  • FIGURE 3. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET RESEARCH PROCESS
  • FIGURE 4. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY C-REACTIVE PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CARDIAC TROPONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CREATINE KINASE-MB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY IN VITRO TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY IN VIVO TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIRECT PURCHASING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY THIRD-PARTY SUPPLIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CENTRAL LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND